Press Releases

Date Title and Summary
Toggle Summary Accuray to Report Second Quarter Fiscal 2022 Financial Results on January 26, 2022
SUNNYVALE, Calif. , Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated  (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the market close on Wednesday, January 26, 2022. Management will host a conference call to review the
Toggle Summary Accuray CyberKnife® Robotic Radiosurgery System Receives Shonin Approval to Treat Trigeminal Neuralgia, a Chronic Pain Condition Affecting a Facial Nerve
- Trigeminal neuralgia, a persistent neurological disorder, is described by some patients as the most excruciating pain human beings can experience(1) - The approval expands global patient access to the CyberKnife System, an effective, non-invasive treatment alternative to surgery SUNNYVALE, Calif.
Toggle Summary Accuray CyberKnife® Robotic Radiotherapy Platform Expands Range of Neurological Indications That Can Be Effectively Treated With Stereotactic Radiosurgery
7,000 Patient Single Institution Analysis Shows Safety, Versatility and Increasing Use of the Advanced Radiotherapy Platform Over a 20-Year Timeframe SUNNYVALE, Calif. , Nov. 10, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that more than two
Toggle Summary Accuray To Participate at Stifel 2021 Virtual Healthcare Conference
Company to present on Tuesday, November 16th, 2021 at 6:20 am PT / 9:20 am ET SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY) today announced its participation in Stifel's 2021 Virtual Healthcare Conference . The management team is scheduled to present on
Toggle Summary Accuray Reports Fiscal 2022 First Quarter Financial Results
Record Revenue First Quarter Fiscal 2022 SUNNYVALE, Calif. , Nov. 3, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021 .     First Quarter Fiscal 2022 Summary Record net revenue of $107.4 million
Toggle Summary Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients
SUNNYVALE, Calif. , Oct. 25, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology  found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast
Toggle Summary Accuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to range between $420 million to $427 million
SUNNYVALE, Calif. , Oct. 21, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY), today announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021 .     Accuray is currently finalizing its financial results for the first quarter of fiscal 2022.
Toggle Summary Accuray Unveils VOLO™ Ultra, the Latest Innovation for the Radixact® System, at ASTRO 2021
Showcases Multiple Forward-Looking Radiotherapy Solutions Designed to Enhance the Treatment Experience for Medical Care Teams and Their Patients SUNNYVALE, Calif. , Oct. 19, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for
Toggle Summary Accuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021
SUNNYVALE, Calif. , Oct. 13, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021 , after the market close on Wednesday, November 3, 2021 . Management will host a conference call to review the
Toggle Summary Accuray to Host ASTRO Analyst & Investor Meeting on October 25, 2021
SUNNYVALE, Calif. , Oct. 12, 2021 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.